{"id":"W3110913480","doi":"10.1093/neuonc/noaa215.242","title":"CTNI-76. PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Delmar (Canada)","funders":"","keywords":"Temozolomide; Tolerability; Medicine; Methyltransferase; Phases of clinical research; O-6-methylguanine-DNA methyltransferase; Internal medicine; Radiation therapy; In vivo; Oncology; Nuclear medicine; Gastroenterology; Clinical trial; Adverse effect; Biology; DNA; Methylation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174418,0.002629456,0.001544464,0.000658667,0.0004956061,0.001241989,0.001609026,0.001256303,0.004763362],"category_scores_gemma":[0.0006592344,0.000703498,0.0008246951,0.0005316627,0.001180186,0.0006936088,0.0004322071,0.003638629,0.00185567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001856559,"about_ca_system_score_gemma":0.003405856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004253581,"about_ca_topic_score_gemma":0.01380663,"domain_scores_codex":[0.9997254,0.00009681143,0.00001061596,0.00004710574,0.00003645646,0.00008358945],"domain_scores_gemma":[0.9996007,0.00002568254,0.00005581221,0.00002711137,0.000019932,0.0002709051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6251603,0.07706021,0.004196783,0.001984938,0.001225097,0.0008335827,0.0004133328,0.01047199,0.1171695,0.001472546,0.01958508,0.1404265],"study_design_scores_gemma":[0.5898132,0.3699473,0.009364155,0.0001353799,0.0004171281,0.0008355506,0.0000828734,0.002997724,0.01426585,0.0004700714,0.01157982,0.00009083376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.974117,0.004972627,0.0006541181,0.001018695,0.0004526413,0.005892837,0.003612276,0.0004034103,0.008876357],"genre_scores_gemma":[0.9634103,0.004355941,0.002978189,0.00138635,0.0002107567,0.005501371,0.006480175,0.00007321441,0.01560374],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004763362,"threshold_uncertainty_score":0.01593506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09570379679146818,"score_gpt":0.4186678264727074,"score_spread":0.3229640296812393,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}